Amicus (FOLD) AI Stock Analysis

• Market Cap: $1.93B
• Dividend Yield: N/A
• Average Volume (3M): 4.81M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: 28.25%
• EPS Growth: 80.86%
• Country: US
• Employees: 499
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 307,930,970
• 10 Day Avg. Volume: 3,616,294
• 30 Day Avg. Volume: 4,811,485
• PEG Ratio: -1.23
• Price to Book (P/B): 9.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 1.13K
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 1.03
• Enterprise Value/Gross Profit: 4.21
• Enterprise Value/Ebitda: 62.16
• 1Y Price Target: $16.00
• Price Target Upside: 154.78% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 61 Neutral
• Price Target: $6.50 ▲(3.50%Upside)

Amicus's overall stock score is primarily influenced by its strong growth outlook and strategic partnerships, as highlighted in the earnings call and recent corporate events. However, financial challenges including high debt levels and ongoing net losses, along with a weak technical position and valuation concerns, moderate the score.

Positive Factors

Market Opportunity

There are currently no FDA-approved treatments for FSGS, creating a potential multi-blockbuster opportunity for FOLD with rare disease pricing.

Market Position

FOLD shares are relatively attractive in the current environment which favors more advanced commercial biopharma companies.

Regulatory Prospects

There has been a major push forward for additional regulatory flexibility in the FSGS indication, and it appears that FOLD wants to take advantage of this progress.

Negative Factors

Biotech Industry Risks

FOLD faces risks common to the biotech industry, including development, regulatory, and manufacturing challenges.

Financial Performance

Amicus' first quarter print came in below expectations and the stock is under pressure after lowering Pombiliti/Opfolda guidance.

Revenue Challenges

Total revenue guidance for FY25 was lowered due to an unexpectedly higher UK VPAG rebate rate.

Amicus Business Overview & Revenue Model

Company Description

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

How the Company Makes Money

Amicus makes money through the development and commercialization of its pharmaceutical products, particularly targeting rare and orphan diseases. The company generates revenue primarily through product sales, especially from its flagship drug Galafold (migalastat), which is used to treat Fabry disease. Additionally, Amicus may also earn income from partnerships and collaborations with other pharmaceutical companies, which can include licensing agreements, milestone payments, and royalties. These strategic partnerships are significant contributors to its earnings, along with government grants or incentives for developing treatments for rare diseases.

Amicus Financial Statement Overview

Summary

Amicus shows strong revenue growth and high gross profit margins, but faces financial instability due to persistent net losses and high debt levels. Improvements in cash flow metrics are noted, yet profitability and financial flexibility challenges remain.

Income Statement

The company shows a positive revenue growth trend with a TTM (Trailing-Twelve-Months) revenue of $543.1 million, up from $528.3 million in the previous annual period. Gross profit margin remains strong at approximately 91%. However, the net profit margin is negative due to consistent net losses, indicating profitability challenges. EBIT and EBITDA margins have improved but remain low, suggesting limited operational efficiency.

Balance Sheet

The company's debt-to-equity ratio is relatively high, indicating significant leverage, which could pose a financial risk. The equity ratio stands at 24.5%, showing a moderate proportion of equity financing. The return on equity is negative due to net losses, highlighting the company's struggle to generate returns for shareholders.

Cash Flow

The free cash flow has turned positive in the TTM period, showing improvement from the previous annual period. The operating cash flow to net income ratio is positive, indicating some level of cash generation from operations. However, the free cash flow to net income ratio remains low, pointing to challenges in converting earnings into cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	528.29M	399.36M	329.23M	305.51M	260.89M
Gross Profit	475.35M	362.03M	290.63M	271.05M	229.84M
EBITDA	29.39M	-92.08M	-199.58M	-202.87M	-242.98M
Net Income	-56.11M	-151.58M	-236.57M	-250.46M	-276.85M
Balance Sheet
Total Assets	785.03M	777.88M	724.17M	905.14M	886.52M
Cash, Cash Equivalents and Short-Term Investments	249.95M	286.20M	293.60M	482.50M	483.27M
Total Debt	443.64M	445.06M	452.12M	440.13M	441.73M
Total Liabilities	590.99M	617.71M	601.12M	597.77M	600.14M
Stockholders Equity	194.04M	160.17M	123.05M	307.37M	286.38M
Cash Flow
Free Cash Flow	-37.44M	-76.53M	-170.34M	-206.38M	-236.52M
Operating Cash Flow	-33.89M	-69.09M	-166.57M	-202.49M	-233.29M
Investing Cash Flow	-560.00K	98.06M	92.32M	78.76M	-13.58M
Financing Cash Flow	5.12M	61.68M	-7.46M	212.07M	262.86M

Amicus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.28
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FOLD, the sentiment is Positive. The current price of 6.28 is above the 20-day moving average (MA) of 6.08, above the 50-day MA of 6.08, and below the 200-day MA of 8.47, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 54.36 is Neutral, neither overbought nor oversold. The STOCH value of 43.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FOLD.

Amicus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FOLD	61 Neutral	$1.93B	―	-18.12%	―	28.25%	80.86%
Sector *	60 Neutral	HK$17.07B	6.10	-7.44%	2.88%	11.55%	-28.15%
APLS	55 Neutral	$2.50B	―	-103.82%	―	48.04%	48.16%
CRNX	54 Neutral	$2.90B	―	-30.84%	―	―	-1.20%
SRRK	50 Neutral	$3.77B	―	-106.71%	―	―	-22.34%
IMVT	45 Neutral	$3.15B	―	-62.46%	―	―	-43.10%
RARE	44 Neutral	$2.65B	―	-386.33%	―	33.46%	26.72%

Amicus Corporate Events

Amicus Stockholders Approve Directors and Equity Plan

At the 2025 Annual Meeting of Stockholders held on June 5, 2025, Amicus‘s stockholders elected four Class III directors for a three-year term and approved the 2025 Equity Incentive Plan. They also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the executive compensation on an advisory basis.

The most recent analyst rating on (FOLD) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Amicus stock, see the FOLD Stock Forecast page.

Amicus Secures License for DMX-200 Development

On April 30, 2025, Amicus Therapeutics entered into a license agreement with Dimerix Bioscience, granting Amicus exclusive rights to develop, manufacture, and commercialize Dimerix’s drug candidate DMX-200 in the United States for Focal Segmental Glomerulosclerosis (FSGS) and other indications. This agreement, effective May 1, 2025, includes a $30 million upfront payment and potential milestone payments totaling up to $560 million. Dimerix will continue funding the ongoing pivotal Phase 3 study for DMX-200, while Amicus will handle regulatory submissions and commercialization in the U.S. This collaboration aims to bring a transformative treatment to patients with FSGS, a rare kidney disease with limited treatment options, enhancing Amicus’s portfolio in the rare disease market.